drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Autologous gene-modified T cells engineered with a chimeric antigen receptor to redirect cytotoxicity against B-cell antigens.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a chimeric antigen receptor that binds B-cell surface antigens (e.g., CD19), enabling antigen recognition and costimulation independent of HLA and triggering T-cell activation, expansion, cytokine release, and perforin/granzyme-mediated lysis of malignant B cells.
drug_name
CAR-T cells
nct_id_drug_ref
NCT06646666